| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 44.8 | 30.5 | 30.8 |
| Other income | 0.7 | 0.1 | 0.1 |
| Total income | 45.5 | 30.6 | 30.9 |
| Profit before exceptional items & tax | 8.1 | 4.9 | 4.2 |
| Profit before tax | 8.1 | 4.9 | 4.2 |
| Net profit | 8.2 | 4.9 | 2.7 |
| Operating margin | 17.8% | 16.0% | 13.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +203.70% |
|---|---|
| Net profit, quarter on quarter | +67.30% |
| Revenue, year on year | +45.50% |
BSE results filing, BSE: 544738. Figures extracted from the filing.
Speciality Medicines Ltd: key numbers
- Share price
- ₹185.00
- Market cap
- ₹162.5 Cr
- Revenue (annual)
- ₹75.29 Cr
- Net profit (annual)
- ₹13.03 Cr
- P/E (TTM)
- 12.5×Sector 47.4×
- Promoter holding
- 43.43%
- FII holding
- 0.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Speciality Medicines Ltd
All →Speciality Medicines Annual Report
Speciality Medicines Limited has submitted its Annual Report for the financial year 2025-26 to the exchange, complying with regulatory filing requirements.
Speciality Medicines Annual General Meeting
Speciality Medicines Limited scheduled its 5th Annual General Meeting for September 28, 2026. The board also approved the draft Directors' Report for FY 2025-26.
Speciality Medicines Regulatory Approval
Speciality Medicines Limited received regulatory approval in Ethiopia for two additional pharmaceutical formulations, Olanzapine and Diazepam tablets. The company now has 12 registered products in Ethiopia.
Speciality Medicines Business Update
Speciality Medicines Limited received regulatory approval for two new products, Olanzapine and Diazepam tablets, in the Ethiopian market, strengthening its international export portfolio.
Speciality Medicines Other Announcement
Speciality Medicines Limited has appointed Capital Bridge Advisory Service Private Limited as its Investor and Public Relations agency to enhance its investor relations and communication efforts.
Speciality Medicines Financial Results
Speciality Medicines Ltd reported its audited standalone financial results for the year ended March 31, 2026. The company also confirmed full utilization of its IPO proceeds.